» Articles » PMID: 19470938

Duration of Chemotherapy for Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis of Randomized Trials

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2009 May 28
PMID 19470938
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine if it is preferable to extend chemotherapy beyond a standard number of cycles in patients receiving first-line chemotherapy for advanced non-small-cell lung cancer.

Methods: We searched biomedical literature databases and conference proceedings for randomized controlled trials (RCTs) comparing a defined number of cycles with continuation of the same chemotherapy until disease progression, a larger defined number of cycles of identical chemotherapy, and a defined number of cycles of identical initial chemotherapy followed by additional cycles of an alternative chemotherapy. Meta-analysis was performed using the fixed effect model. The primary outcome was overall survival (OS); secondary outcomes included progression-free survival (PFS), adverse events (AE), and health-related quality of life (HRQL).

Results: We found 13 RCTs including 3,027 patients. Extending chemotherapy improved PFS substantially (hazard ratio [HR], 0.75; 95% CI, 0.69 to 0.81; P < .00001) and OS modestly (HR, 0.92; 95% CI, 0.86 to 0.99; P = .03). Subgroup analysis revealed that effects on PFS were greater for trials extending chemotherapy with third-generation regimens rather than older regimens (HR, 0.70 interaction v 0.92 interaction; P = .003). Extending chemotherapy was associated with more frequent AE in all trials where it was reported and impaired HRQL in two of seven trials.

Conclusion: Extending chemotherapy, particularly with a third-generation regimen, improved PFS substantially, but OS less so. Future trials should test extending treatment with more effective and/or better-tolerated agents.

Citing Articles

Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer.

Jiang W, Sun W, Li W, Gao J, Wang H, Zhou W Sci Rep. 2022; 12(1):10841.

PMID: 35761010 PMC: 9237081. DOI: 10.1038/s41598-022-14222-w.


Apatinib inhibits macrophage-mediated epithelial-mesenchymal transition in lung cancer.

Liu S, Su L, Mu X, Shi Y, Zhang A, Ge X RSC Adv. 2022; 8(38):21451-21459.

PMID: 35539916 PMC: 9080926. DOI: 10.1039/c8ra01231h.


Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.

Chang X, Liu Z, Man S, Roys A, Li Z, Zuo D RSC Adv. 2022; 9(31):17921-17932.

PMID: 35520562 PMC: 9064669. DOI: 10.1039/c9ra02258a.


Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.

Liu Y, Li H, Wang R Front Med (Lausanne). 2021; 8:616380.

PMID: 34277647 PMC: 8277997. DOI: 10.3389/fmed.2021.616380.


DDIAS promotes invasion and proliferation of non-small cell lung cancer and predicts poor survival of lung cancer patients.

Liu N, Zhang X, Zhou H, Cai L, Li A, Miao Y Int J Clin Exp Pathol. 2020; 10(12):11506-11515.

PMID: 31966506 PMC: 6966031.